<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-159927" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mupirocin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Erwin</surname>
            <given-names>Dylan Z.</given-names>
          </name>
          <aff>UT Health San Antonio</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chen</surname>
            <given-names>Philip</given-names>
          </name>
          <aff>University of Texas Health San Antonio</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dylan Erwin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Philip Chen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-159927.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Mupirocin belongs to the topical antibiotic class of medications and is utilized for managing and treating various skin and soft tissue infections.&#x000a0;Mupirocin was originally developed in the early 1970s and is derived from&#x000a0;<italic toggle="yes">Pseudomonas fluorescens</italic><italic toggle="yes">.</italic><xref ref-type="bibr" rid="article-159927.r1">[1]</xref><xref ref-type="bibr" rid="article-159927.r2">[2]</xref> Mupirocin is recognized as the most widely used topical antibiotic globally for treating methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA), particularly in cases of impetigo.<xref ref-type="bibr" rid="article-159927.r3">[3]</xref>&#x000a0;Proper administration of mupirocin effectively eliminates infectious symptoms in over 85% of impetigo cases.<xref ref-type="bibr" rid="article-159927.r2">[2]</xref> Mupirocin has consistently demonstrated its efficacy in eradicating intranasal MRSA colonization in healthcare settings.<xref ref-type="bibr" rid="article-159927.r3">[3]</xref> The topical medication mupirocin received initial approval from the U.S. Food and Drug Administration (FDA) in 1997,<xref ref-type="bibr" rid="article-159927.r4">[4]</xref>&#x000a0;and has since been widely prescribed and used globally.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The initial FDA approval was restricted to the topical administration for superficial skin infections.<xref ref-type="bibr" rid="article-159927.r4">[4]</xref> The specific FDA indication for mupirocin is its topical use in treating impetigo caused by <italic toggle="yes">S aureus</italic> and <italic toggle="yes">Streptococcus pyogenes</italic>, as stated in the FDA guidelines for Bactroban.<italic toggle="yes"/></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Beyond its approved topical administration for skin infections, off-label usage and ongoing research are investigating new applications of mupirocin, including its potential efficacy against deeper infections and non-typical bacteria, such as <italic toggle="yes">Neisseria gonorrhoeae</italic>.<xref ref-type="bibr" rid="article-159927.r5">[5]</xref> Interestingly, mupirocin has found off-label applications in managing otorrhea associated with tympanostomy tubes, serving as an additive in sinonasal irrigations, and acting as prophylaxis to prevent peritoneal dialysis catheter site infection.<xref ref-type="bibr" rid="article-159927.r6">[6]</xref><xref ref-type="bibr" rid="article-159927.r7">[7]</xref><xref ref-type="bibr" rid="article-159927.r8">[8]</xref> In tympanostomy tube otorrhea cases, mupirocin has effectively reduced drainage by providing reliable coverage of the middle ear flora.<xref ref-type="bibr" rid="article-159927.r6">[6]</xref></p>
        <p>In the treatment of chronic rhinosinusitis, mupirocin has demonstrated the ability to decrease intranasal <italic toggle="yes">Staphylococcus</italic> levels, theoretically reducing biofilm formation that may contribute to sinusitis symptoms.<xref ref-type="bibr" rid="article-159927.r7">[7]</xref> Prophylactic application of mupirocin to peritoneal dialysis catheter sites has been shown to lower infection rates.<xref ref-type="bibr" rid="article-159927.r8">[8]</xref> Furthermore, mupirocin has been used off-label to promote the wound healing process, with the underlying mechanism believed to be associated with increased keratinocyte proliferation.<xref ref-type="bibr" rid="article-159927.r9">[9]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-159927.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Mupirocin, also known as pseudomonic acid A, is a short-chain fatty acid and the primary fermentation metabolite of <italic toggle="yes">P fluorescens.</italic><xref ref-type="bibr" rid="article-159927.r10">[10]</xref><xref ref-type="bibr" rid="article-159927.r11">[11]</xref> Mupirocin is believed to exert its antimicrobial activity by inhibiting isoleucyl-transfer RNA, thereby obstructing bacterial protein and RNA synthesis, ultimately resulting in cell death.<xref ref-type="bibr" rid="article-159927.r10">[10]</xref> This mechanism occurs due to the similarity between a mupirocin protein side chain and the bacterial isoleucyl-transfer RNA binding site, which leads to mupirocin incorporation into the binding site. When bacterial isoleucyl-transfer RNA is obstructed, cellular levels of charged transfer RNA are depleted, causing the cessation of protein and RNA synthesis. This, in turn, results in bacterial cell death, particularly at elevated concentrations of mupirocin.</p>
        <p>Interestingly, mupirocin has demonstrated bacteriostatic effects attributed to reduced side-chain binding at lower concentrations.<xref ref-type="bibr" rid="article-159927.r12">[12]</xref> This antibiotic exhibits broad antibacterial coverage against gram-positive and certain gram-negative bacteria,&#x000a0;with notable susceptibility observed in skin infections caused by staphylococci and streptococci.<xref ref-type="bibr" rid="article-159927.r5">[5]</xref><xref ref-type="bibr" rid="article-159927.r13">[13]</xref> Interestingly, mupirocin exhibits minimal impact on typical normal skin flora, including <italic toggle="yes">Propionibacterium</italic>, potentially contributing to preserving the skin's natural defense mechanisms.<xref ref-type="bibr" rid="article-159927.r13">[13]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Mupirocin generally demonstrates minimal systemic absorption, accounting for less than&#x000a0;1%, which aided its FDA approval.<xref ref-type="bibr" rid="article-159927.r5">[5]</xref></p>
        <p><bold>Distribution:</bold> The systemic absorption of mupirocin occurs secondary to diffusion through the stratus corneum, reaching the intercellular space and allowing absorption. However, over 98% of applied mupirocin does not diffuse through the stratum corneum.<xref ref-type="bibr" rid="article-159927.r14">[14]</xref></p>
        <p><bold>Metabolism:</bold> Mupirocin has a half-life of approximately 15 minutes, with predominant systemic metabolism&#x000a0;occurring&#x000a0;in the kidneys.<xref ref-type="bibr" rid="article-159927.r15">[15]</xref> Although systemic absorption and excretion occur through the kidneys, most topically applied mupirocin is eliminated through the upward movement and desquamation of skin cells rather than systemic pathways, as previously discussed.<xref ref-type="bibr" rid="article-159927.r16">[16]</xref> The local concentration of mupirocin has been observed to increase 5- to 10-fold when an occlusive dressing is applied after the administration of topical mupirocin.<xref ref-type="bibr" rid="article-159927.r16">[16]</xref> Furthermore, the activity of mupirocin has been shown to decrease in environments that are more alkalotic than the skin.<xref ref-type="bibr" rid="article-159927.r17">[17]</xref></p>
        <p><bold>Elimination:</bold> The primary route of systemic excretion for mupirocin is through the kidneys.<xref ref-type="bibr" rid="article-159927.r15">[15]</xref></p>
      </sec>
      <sec id="article-159927.s3" sec-type="Administration">
        <title>Administration</title>
        <p><bold>Available Dosage Forms and Strengths:</bold>&#x000a0;Mupirocin is available in various formulations in the United States. Although the most common prescription is in the form of a topical ointment, it has also been studied in intramuscular and cream formulations.<xref ref-type="bibr" rid="article-159927.r18">[18]</xref><xref ref-type="bibr" rid="article-159927.r19">[19]</xref></p>
        <p>The most widely accessible topical formulation is a&#x000a0;2% ointment in a water-miscible polyethylene glycol base, typically packaged in a 22-g container, with each gram containing 20 &#x003bc;g of mupirocin.<xref ref-type="bibr" rid="article-159927.r10">[10]</xref></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>The typical recommended dosage for adults is to apply approximately 0.5 g of mupirocin 2 to 3 times a day for up to 10 days.<xref ref-type="bibr" rid="article-159927.r20">[20]</xref>&#x000a0;</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p>Specific recommendations are not provided for pregnant, pediatric, and geriatric populations, as well as individuals with hepatic impairment, due to minimal systemic absorption. In the case of pediatric populations aged 2 months and older, FDA approval supports the use of topical mupirocin in individuals.</p>
        <p>Due to systemic renal excretion, mupirocin&#x000a0;may be considered with caution in individuals with severe renal impairment, particularly due to the presence of polyethylene glycol and the associated risk of nephrotoxicity.<xref ref-type="bibr" rid="article-159927.r20">[20]</xref> Furthermore, for breastfeeding mothers, it is advisable to cleanse&#x000a0;the breast treated with mupirocin before breastfeeding their infants due to unknown effects. However, substantial transmission via breast milk is not expected due to minimal systemic absorption of mupirocin.<xref ref-type="bibr" rid="article-159927.r20">[20]</xref></p>
      </sec>
      <sec id="article-159927.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Drug Reactions</bold>
</p>
        <p>Topical mupirocin is generally well-tolerated, with the most frequently reported adverse effect being mild contact dermatitis, characterized by burning, stinging, or pain.<xref ref-type="bibr" rid="article-159927.r21">[21]</xref> Additional rare and mild adverse effects include pruritis, dry skin, or erythema.<xref ref-type="bibr" rid="article-159927.r21">[21]</xref>&#x000a0;Although more severe adverse effects have been rarely reported, they theoretically include potentially life-threatening angioedema or anaphylactic reactions.<xref ref-type="bibr" rid="article-159927.r20">[20]</xref></p>
        <p>Additional rare adverse effects of mupirocin have been documented with mucosal usage. When mupirocin is applied to the conjunctiva or nasal mucosa, local irritation, and unpleasant taste and smell have been reported.<xref ref-type="bibr" rid="article-159927.r17">[17]</xref> Otherwise, no systemic adverse effects have been reported.<xref ref-type="bibr" rid="article-159927.r20">[20]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Drug interactions are also rare for topical mupirocin due to minimal systemic absorption, and, overall, none have been reported or listed in mupirocin's FDA approval.<xref ref-type="bibr" rid="article-159927.r22">[22]</xref></p>
      </sec>
      <sec id="article-159927.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warnings and Precautions</bold>
</p>
        <p>As per&#x000a0;FDA regulations and approval, the only specific contraindication for mupirocin is known hypersensitivity reactions to the medication or its components. FDA precautions include potential allergic reactions, eye and local irritations, theoretical risk of <italic toggle="yes">Clostridium difficile&#x02013;</italic>associated&#x000a0;diarrhea, microbial overgrowth, unknown mucosal effects, interactions with polyethylene glycol, and the potential for fungal or bacterial overgrowth with usage at intravenous catheter sites, as stated in the FDA guidelines for Bactroban.</p>
      </sec>
      <sec id="article-159927.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>When treating topical skin infections, healthcare professionals should be mindful that infections may worsen or secondary infections may occur. Therefore, mupirocin usage is generally recommended for no more than 10 days unless specifically directed by a physician. Monitoring should involve a dermatologic examination for skin changes or systemic symptoms that may indicate a worsening infection or allergic reaction. Signs of a reaction may include increased erythema and pruritus, whereas worsened infection may also present with increased erythema, induration, and pain.<xref ref-type="bibr" rid="article-159927.r20">[20]</xref><xref ref-type="bibr" rid="article-159927.r22">[22]</xref></p>
        <p>Resistance to mupirocin is believed to be on the rise in recent years, particularly among <italic toggle="yes">S</italic><italic toggle="yes">&#x000a0;aureus</italic> and MRSA isolates.<xref ref-type="bibr" rid="article-159927.r23">[23]</xref> Studies indicate a significant proportion of mupirocin-resistant <italic toggle="yes">Staphylococcus</italic> isolates, many of which are also methicillin-resistant.<xref ref-type="bibr" rid="article-159927.r3">[3]</xref> Resistance is primarily attributed to the widespread prescription of mupirocin, along with its frequent use by medical professionals as a topical treatment with perceived low risk, and patients exceeding recommended usage durations. The routine use in healthcare settings for intranasal MRSA eradication may also be a contributing factor.<xref ref-type="bibr" rid="article-159927.r24">[24]</xref></p>
        <p>Resistance arises from alterations in bacterial isoleucyl-transfer RNA, resulting in the loss of mupirocin side chain recognition and the subsequent failure of mupirocin insertion at the binding site.<xref ref-type="bibr" rid="article-159927.r23">[23]</xref> Two common types of resistance to mupirocin are described, with high-level resistance resulting from plasmid-mediated gene mutations and low-level resistance associated with chromosomal point mutations.<xref ref-type="bibr" rid="article-159927.r23">[23]</xref> A recent meta-analysis reveals a resistance rate of approximately 7.6% among <italic toggle="yes">S aureus</italic> isolates compared to about&#x000a0;13.8% resistance among MRSA isolates.<xref ref-type="bibr" rid="article-159927.r23">[23]</xref> Interestingly, North and South America were shown to have higher rates of mupirocin resistance when compared to the rest of the world.<xref ref-type="bibr" rid="article-159927.r23">[23]</xref></p>
      </sec>
      <sec id="article-159927.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Currently, no available study or report suggests&#x000a0;that using topical mupirocin consistently causes systemic toxicity. As previously stated, caution is advised in individuals with severe renal impairment and those with large open wounds due to the potential for increased absorption and nephrotoxicity. In such cases, renal function should be closely monitored with scheduled renal function panels,&#x000a0;as stated in the FDA guidelines for Bactroban.</p>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>No specific case of overdose has been reported in the current literature with topical mupirocin usage. However, as discussed, there is a potential for renal toxicity, which may be considered an overdose.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>In cases of concern for renal toxicity, immediate discontinuation of mupirocin is recommended, and a qualified medical professional should promptly evaluate renal function.</p>
      </sec>
      <sec id="article-159927.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Topical mupirocin has been commonly used and available for several decades.<xref ref-type="bibr" rid="article-159927.r1">[1]</xref> The widespread availability and perceived safety have contributed to the significant overuse of mupirocin.<xref ref-type="bibr" rid="article-159927.r23">[23]</xref> Consequently, all healthcare team members should be aware of the overall increase in bacterial resistance associated with mupirocin usage. In addition, as new data emerge, it is imperative for healthcare professionals to stay up-to-date on evolving treatment recommendations for mupirocin usage. This includes considerations for tympanostomy tube otorrhea, peritoneal dialysis catheter site infection prevention, sinonasal irrigations, and intramuscular activity against non-typical bacteria.</p>
        <p>Due to the potential risks of local reaction and dermatitis, healthcare professionals should be well-versed and up-to-date on the proper usage and recommendations for topical mupirocin. In cases of a prior history of a reaction to mupirocin or its contents, healthcare professionals should advise against future use of the drug. Furthermore, monitoring the response and potential adverse effects is a crucial responsibility of the healthcare team.</p>
        <p>Mupirocin may be cautiously used in patients with renal impairment or renal failure. Ensuring patient safety requires the coordination and collaboration of the entire healthcare team to monitor patients for potential toxicity. In cases of renal impairment, pharmacists should carefully consider alternative options.</p>
      </sec>
      <sec id="article-159927.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=159927&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=159927">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/159927/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=159927">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-159927.s10">
        <title>References</title>
        <ref id="article-159927.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurney</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Mupirocin: biosynthesis, special features and applications of an antibiotic from a gram-negative bacterium.</article-title>
            <source>Appl Microbiol Biotechnol</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>90</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-21</page-range>
            <pub-id pub-id-type="pmid">21336932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pappa</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>The clinical development of mupirocin.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1990</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5 Pt 1</issue>
            <fpage>873</fpage>
            <page-range>873-9</page-range>
            <pub-id pub-id-type="pmid">2112164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shivanna</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dasegowda</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Disk Diffusion and Agar Dilution Method for the Detection of Mupirocin Resistance in Staphylococcal Isolates from Skin and Soft Tissue Infections.</article-title>
            <source>J Lab Physicians</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>372</fpage>
            <page-range>372-376</page-range>
            <pub-id pub-id-type="pmid">37564234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cern</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bavli</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hod</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zilbersheid</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mushtaq</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Michael-Gayego</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barasch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Feinstein Rotkopf</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Livermore</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Barenholz</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Potential of Injectable Nano-Mupirocin Liposomes for Infections Involving Multidrug-Resistant Bacteria.</article-title>
            <source>Pharmaceutics</source>
            <year>2021</year>
            <month>Dec</month>
            <day>17</day>
            <volume>13</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">34959466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tucaliuc</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blaga</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Galaction</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Cascaval</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Mupirocin: applications and production.</article-title>
            <source>Biotechnol Lett</source>
            <year>2019</year>
            <month>May</month>
            <volume>41</volume>
            <issue>4-5</issue>
            <fpage>495</fpage>
            <page-range>495-502</page-range>
            <pub-id pub-id-type="pmid">30927135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isaacson</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Oxymetazoline, Mupirocin, Clotrimazole-Safe, Effective, Off-Label Agents for Tympanostomy Tube Care.</article-title>
            <source>Ear Nose Throat J</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>99</volume>
            <issue>1_suppl</issue>
            <fpage>30S</fpage>
            <page-range>30S-34S</page-range>
            <pub-id pub-id-type="pmid">32182136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adappa</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Nasal irrigation with or without drugs: the evidence.</article-title>
            <source>Curr Opin Otolaryngol Head Neck Surg</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-7</page-range>
            <pub-id pub-id-type="pmid">22143336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lau</surname>
                <given-names>EPM</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Charlesworth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vekaria</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Filion</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chakera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YCG</given-names>
              </name>
            </person-group>
            <article-title>Topical antibiotics prophylaxis for infections of indwelling pleural/peritoneal catheters (TAP-IPC): A pilot study.</article-title>
            <source>Respirology</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-182</page-range>
            <pub-id pub-id-type="pmid">37696757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Twilley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reva</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lall</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Mupirocin Promotes Wound Healing by Stimulating Growth Factor Production and Proliferation of Human Keratinocytes.</article-title>
            <source>Front Pharmacol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>862112</fpage>
            <pub-id pub-id-type="pmid">35479318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parenti</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hatfield</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Leyden</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Mupirocin: a topical antibiotic with a unique structure and mechanism of action.</article-title>
            <source>Clin Pharm</source>
            <year>1987</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>10</issue>
            <fpage>761</fpage>
            <page-range>761-70</page-range>
            <pub-id pub-id-type="pmid">3146455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Booth</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Benrimoj</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Mupirocin in the treatment of impetigo.</article-title>
            <source>Int J Dermatol</source>
            <year>1992</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">1737680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khoshnood</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Heidary</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Asadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soleimani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Motahar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Savari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abdi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A review on mechanism of action, resistance, synergism, and clinical implications of mupirocin against Staphylococcus aureus.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>109</volume>
            <fpage>1809</fpage>
            <page-range>1809-1818</page-range>
            <pub-id pub-id-type="pmid">30551435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sutherland</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boon</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Masters</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Slocombe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1985</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>495</fpage>
            <page-range>495-8</page-range>
            <pub-id pub-id-type="pmid">3923922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dorrani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>LaVoie</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Pilch</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Michniak-Kohn</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>TXA497 as a topical antibacterial agent: comparative antistaphylococcal, skin deposition, and skin permeation studies with mupirocin.</article-title>
            <source>Int J Pharm</source>
            <year>2014</year>
            <month>Dec</month>
            <day>10</day>
            <volume>476</volume>
            <issue>1-2</issue>
            <fpage>199</fpage>
            <page-range>199-204</page-range>
            <pub-id pub-id-type="pmid">25263100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poovelikunnel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gethin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>70</volume>
            <issue>10</issue>
            <fpage>2681</fpage>
            <page-range>2681-92</page-range>
            <pub-id pub-id-type="pmid">26142407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conly</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Mupirocin - Are we in danger of losing it?</article-title>
            <source>Can J Infect Dis</source>
            <year>2002</year>
            <month>May</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>157</fpage>
            <page-range>157-9</page-range>
            <pub-id pub-id-type="pmid">18159385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Punjataewakupt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Napavichayanun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aramwit</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The downside of antimicrobial agents for wound healing.</article-title>
            <source>Eur J Clin Microbiol Infect Dis</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-54</page-range>
            <pub-id pub-id-type="pmid">30291466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cern</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Jerse</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Barenholz</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title><italic>In Vitro</italic> Susceptibility of Neisseria gonorrhoeae Strains to Mupirocin, an Antibiotic Reformulated for Parenteral Administration in Nanoliposomes.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">29339382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gisby</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>255</fpage>
            <page-range>255-60</page-range>
            <pub-id pub-id-type="pmid">10639346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campoli-Richards</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.</article-title>
            <source>Drugs</source>
            <year>1986</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>425</fpage>
            <page-range>425-44</page-range>
            <pub-id pub-id-type="pmid">3098541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rumsfield</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>IK</given-names>
              </name>
            </person-group>
            <article-title>Topical mupirocin in the treatment of bacterial skin infections.</article-title>
            <source>Drug Intell Clin Pharm</source>
            <year>1986</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>12</issue>
            <fpage>943</fpage>
            <page-range>943-8</page-range>
            <pub-id pub-id-type="pmid">3102197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coondoo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chattopadhyay</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Drug interactions in dermatology: what the dermatologist should know.</article-title>
            <source>Indian J Dermatol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>249</fpage>
            <page-range>249-54</page-range>
            <pub-id pub-id-type="pmid">23918993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dadashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hajikhani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Darban-Sarokhalil</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>van Belkum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goudarzi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Mupirocin resistance in Staphylococcus aureus: A systematic review and meta-analysis.</article-title>
            <source>J Glob Antimicrob Resist</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>20</volume>
            <fpage>238</fpage>
            <page-range>238-247</page-range>
            <pub-id pub-id-type="pmid">31442624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159927.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Gorwitz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Jernigan</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Mupirocin resistance.</article-title>
            <source>Clin Infect Dis</source>
            <year>2009</year>
            <month>Sep</month>
            <day>15</day>
            <volume>49</volume>
            <issue>6</issue>
            <fpage>935</fpage>
            <page-range>935-41</page-range>
            <pub-id pub-id-type="pmid">19673644</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
